Phase 1 Oncology Deal Benchmarks

Median Upfront

$90M

Range: $42M - $138M

Total Deal Value

$882M

Range: $485M - $1.3B

Royalty Rate

8.6% - 15%

Tiered up to 19%

Dev Milestones

$317M

Range: $177M - $456M

Model Your Deal

Market Analysis

Phase 1 oncology licensing deals carry a median total deal value of $882M, with upfront payments ranging from $42M to $138M. At this stage, deal structures are heavily milestone-weighted, reflecting the significant clinical risk ahead. The recommended split allocates 10% to upfront and 90% to milestones.

The oncology landscape at the phase 1 stage is characterized by high competitive intensity with numerous active programs and a rapidly evolving standard of care. Development milestones average $317M, regulatory milestones contribute $277M, and commercial milestones reach $198M. ADCs, bispecifics, and radiopharmaceuticals continue to drive premium valuations across solid and hematologic tumors.

Royalty rates for phase 1 oncology deals range from 8.6% to 15% at the base tier, with high-tier escalation to 19%. Earlier-stage royalties are at the lower end of industry ranges, reflecting higher clinical risk.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the average upfront payment for phase 1 oncology deals?

Phase 1 oncology deals average $90M in upfront payments, ranging from $42M to $138M. The upfront allocation of 10% of total deal value reflects the clinical stage risk profile.

How are phase 1 oncology deal milestones structured?

Milestones account for approximately 90% of total deal value. Development milestones ($317M) represent the largest component, followed by commercial milestones ($198M) and regulatory milestones ($277M).

What royalty rates are typical for phase 1 oncology licensing?

Base royalty rates range from 8.6% to 15%, with tiered escalation to 12.6%-19% on peak sales. Rates are influenced by modality, competitive positioning, and territorial scope.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

Phase 1 Oncology Deal Benchmarks

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

Preclinical Oncology Deals

Phase 1/2 Oncology Deals

Phase 1 Neurology Deals

Phase 1 Immunology & Autoimmune Deals

Ready to Calculate Your Deal Terms?